Mucoangin Zitrone (Ambroxol Hydrochloride)

Ambroxol stimulates surfactant production and increases ciliary activity in the airway epithelium. By breaking down mucopolysaccharide bonds, it reduces mucus viscosity and promotes the secretion of serous fluid, which together enhance the transport and clearance of mucus from the lungs.

The appropriate dose of Mucoangin Zitrone is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and overall health. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety data for Ambroxol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant or breastfeeding should discuss the treatment with their physician before starting therapy.

To order Mucoangin Zitrone, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ambroxol differs from simple expectorants such as guaifenesin by actively stimulating surfactant production and ciliary motion, which not only thins mucus but also enhances its transport. This dual action can provide more rapid symptom relief in patients with thick, tenacious secretions.

Mucoangin Zitrone should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mucoangin Zitrone is intended for oromucosal administration. The tablet (or oral formulation) is taken by mouth and allowed to dissolve or be swallowed with a glass of water, following the dosage instructions provided by the prescriber.

Serious adverse reactions, although rare, include allergic responses such as hives, swelling, or anaphylaxis, severe skin conditions like Stevens‑Johnson syndrome, hepatic dysfunction indicated by elevated liver enzymes, and bronchospasm that may worsen breathing difficulties. Any of these symptoms require immediate medical attention.

Mucoangin Zitrone should be avoided in individuals with a known hypersensitivity to Ambroxol or any of the product’s excipients. Patients with uncontrolled severe asthma or those who have experienced bronchospasm with mucolytics should consult a physician before use.